| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Jun 14, 2024 | REPLIGEN CORP | Director | Buy | 95.0 | +1,200 | 34.60% | ✗ | $150.5K |
| May 11, 2022 | May 13, 2022 | Twist Bioscience Corp | Director | Buy | 97.5 | +8,550 | 158.66% | ✗ | $250.1K |
| Oct 29, 2021 | Nov 2, 2021 | REPLIGEN CORP | Director | Sell | 20.0 | -1,645 | -51.54% | ✗ | $474.1K |
| Jun 23, 2021 | Jun 25, 2021 | 908 Devices Inc. | VP, Corporate Development | Sell | 7.5 | -13,000 | -48.98% | ✓ | $516.4K |
| Feb 9, 2021 | Feb 11, 2021 | Twist Bioscience Corp | Director | Sell | 20.0 | -5,000 | -72.48% | ✗ | $888K |
| Dec 22, 2020 | Dec 22, 2020 | 908 Devices Inc. | Director | Buy | 97.5 | +14,000 | 100.00% | ✗ | $280K |
| Nov 9, 2020 | Nov 10, 2020 | REPLIGEN CORP | Director | Sell | 22.5 | -1,214 | -45.57% | ✗ | $237.3K |
| May 18, 2020 | May 26, 2020 | REPLIGEN CORP | Director | Sell | 20.0 | -3,009 | -53.04% | ✗ | $428.9K |
| Apr 22, 2020 | Apr 24, 2020 | REPLIGEN CORP | Director | Sell | 20.0 | -2,688 | -46.95% | ✗ | $295.7K |
| Apr 3, 2020 | Apr 6, 2020 | REPLIGEN CORP | Director | Sell | 20.0 | -2,688 | -39.76% | ✗ | $268.8K |
| Mar 6, 2020 | Mar 10, 2020 | STANDARD BIOTOOLS INC. | Director | Buy | 95.0 | +80,000 | 115.32% | ✗ | $243.9K |
| Feb 13, 2020 | Feb 18, 2020 | STANDARD BIOTOOLS INC. | Director | Buy | 91.3 | +12,257 | 21.46% | ✗ | $44.6K |
| Jun 17, 2019 | Jun 19, 2019 | STANDARD BIOTOOLS INC. | Director | Sell | 25.0 | -5,100 | -10.86% | ✓ | $63.4K |
| Aug 29, 2018 | Aug 31, 2018 | REPLIGEN CORP | Director | Sell | 20.0 | -6,580 | -61.12% | ✗ | $358.2K |
| May 9, 2018 | May 11, 2018 | REPLIGEN CORP | Director | Sell | 17.5 | -26,500 | -84.52% | ✗ | $1.1M |